Press release
Deadline on Dec.23rd coming up for Investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares
A Deadline is coming up on December 23, 2019 in the lawsuit for certain investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
Investors who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and there are strict and short deadlines running. Deadline: December 23, 2019. NASDAQ: ZYNE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) common shares between March 11, 2019, and September 17, 2019, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between March 11, 2019, and September 17, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial, that the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Dec.23rd coming up for Investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares here
News-ID: 1877317 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Zynerba
Psychoactive Substances Market Forecast 2031|Zynerba Pharmaceuticals, GW Pharmac …
[Nevada, October 2024] - Psychoactive substances encompass a wide range of materials that influence mental processes and alter consciousness. These substances can be found in various forms, including natural compounds, synthetic drugs, and designer substances. The psychoactive substances market has gained significant attention in recent years due to shifting societal attitudes, evolving regulatory landscapes, and increased consumer demand. As psychological health and wellness continue to be at the forefront of…
Lymphatic Malformations Market to Observe Impressive Growth During the Forecast …
According to DelveInsight's evaluations, the market for Lymphatic Malformations (LM) in the seven major markets (7MM) is expected to expand significantly in the coming years. Within the 7MM, the United States holds the largest market size for Lymphatic Malformations, surpassing the combined market size of the EU5 (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
Currently, there are only a limited number of pipeline products in clinical development for…
Robust Growth OF Autism Spectrum Disorder Therapeutics Market Overall Study Repo …
The Coherent Market Insights latest study report on changing dynamics of each of the segments and subsegments of the "Autism Spectrum Disorder Therapeutics Market" and examines the investment in the market from 2024-2031. The research report contains all of the relevant facts. It provides market insight by providing accurate data to its clients, allowing them to make critical decisions. It provides an overview of the Autism Spectrum Disorder Therapeutics market,…
Explosive growth on New Psychoactive Substance Market 2021-2027| Zynerba Pharmac …
Leaders throughout the nation are looking for innovative methods to combat the increasing dependence crisis. As the most important treatment methods Prescription medicines designated as prohibited hazardous substances are generally accepted in different medical circumstances. Many prescription medications have pleasurable side effects which can attract patients to utilize these medicines for other applications than the approved ones. Prescription drug abuse or misuse may contribute to addictive behavior, the major risk…
Investigation announced for Long-Term Investors in shares of Zynerba Pharmaceuti …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Zynerba Pharmaceuticals, Inc.
Investors who are current long term investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ZYNE stocks follows a lawsuit filed against Zynerba Pharmaceuticals,…
Postoperative Management Market is Flourishing Worldwide || Boehringer Ingelheim …
The Global Postoperative Management Market is expected to reach USD 105.8 million by 2025, from USD 67.4 billion in 2017, growing at a CAGR of 5.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-postoperative-management-market
Some of the major…
